Journey Medical Corporation to Announce Second Quarter 2026 Financial Results on August 12, 2026

Rhea-AI Summary

Journey Medical (Nasdaq: DERM) will release its second quarter 2026 financial results after U.S. markets close on Wednesday, August 12, 2026. Management will host a conference call and live audio webcast the same day at 4:30 p.m. ET to discuss results and provide a corporate update.

U.S. participants can dial 1-866-777-2509, international participants 1-412-317-5413, or register online to receive dial-in details. The webcast will be available via the Investors section of Journey Medical’s website and remain accessible for approximately 30 days after the call.

Market Context

The prior earnings-date notices recorded -4.03% and -5.07% 24-hour reactions (news_ids 1052405 and 1...

Analysis

The prior earnings-date notices recorded -4.03% and -5.07% 24-hour reactions (news_ids 1052405 and 1028670). This notice supplies timing, not results; moderate short positioning is a sourced risk, while the upcoming release provides the substantive checkpoint.

Key Figures

Reporting period: Q2 2026 Results release date: August 12, 2026 Conference call time: 4:30 p.m. ET +2 more

5 metrics

Reporting period Q2 2026 Financial results release

Results release date August 12, 2026 After U.S. financial markets close

Conference call time 4:30 p.m. ET August 12, 2026

Branded prescription drugs Nine drugs Currently marketed FDA-approved products

Webcast replay Approximately 30 days Availability after the conference call

Previous Earnings date Reports

2 past events · Latest: May 06 (Neutral)

Same Type Pattern 2 events

Date	Event	Sentiment	24h Move	Catalyst
May 06	Earnings date	Neutral	-4.0%	Prior notice of first-quarter results produced a negative 24-hour price reaction.
Mar 18	Earnings date	Neutral	-5.1%	Prior notice of year-end results produced a negative 24-hour price reaction.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Both tag-matched earnings-date notices were followed by negative 24-hour reactions: -4.03% and -5.07%.

Key Terms

fda-approved

1 terms

fda-approved regulatory

"FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions"

FDA-approved means a medical product, drug, device or treatment has passed the U.S. Food and Drug Administration’s review for safety and effectiveness for a specific use. Think of it like a formal safety and performance seal that allows the product to be marketed for that purpose in the U.S.; for investors, approval reduces regulatory uncertainty, enables sales and reimbursement pathways, and can materially affect a company’s revenue prospects and valuation.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Company to host conference call to discuss financial results and provide a corporate update on August 12, 2026 at 4:30 p.m. ET

SCOTTSDALE, Ariz., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or the “Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company primarily focused on developing, selling and marketing U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced the Company will release its second quarter 2026 financial results after the U.S. financial markets close on Wednesday, August 12, 2026. Journey Medical management will conduct a conference call and audio webcast on Wednesday, August 12, 2026 at 4:30 p.m. ET.

To listen to the conference call, interested parties within the U.S. should dial 1-866-777-2509 (domestic) or 1-412-317-5413 (international). All callers should dial in approximately 10 minutes prior to the scheduled start time and ask to join the Journey Medical conference call. Participants can register for the conference by navigating to https://dpregister.com/sreg/10210876/1048acbd764. Please note that registered participants will receive their dial-in number upon registration.

A live audio webcast can be accessed on the News and Events page of the Investors section of Journey Medical’s website, www.journeymedicalcorp.com, and will remain available for replay for approximately 30 days after the conference call.

About Journey Medical Corporation
Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical”) is a commercial-stage pharmaceutical company that primarily focuses on developing, selling and marketing FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions through its efficient sales and marketing model. The Company currently markets nine branded FDA-approved prescription drugs that help treat and heal common skin conditions. The Journey Medical team comprises industry experts with extensive experience in developing and commercializing some of dermatology’s most successful prescription brands. Journey Medical is located in Scottsdale, Arizona and was founded by Fortress Biotech, Inc. (Nasdaq: FBIO). Journey Medical’s common stock is registered under the Securities Exchange Act of 1934, as amended, and it files periodic reports with the U.S. Securities and Exchange Commission (“SEC”). For additional information about Journey Medical, visit www.journeymedicalcorp.com.

Company Contact:
Jaclyn Jaffe
Journey Medical Corporation
(781) 652-4500
ir@jmcderm.com

Media Relations Contact:
Tony Plohoros
6 Degrees
(908) 591-2839
tplohoros@6degreespr.com  

FAQ

When will Journey Medical (NASDAQ: DERM) report its Q2 2026 earnings?

Journey Medical plans to report its Q2 2026 financial results on Wednesday, August 12, 2026, after U.S. markets close. According to Journey Medical, management will also host a conference call and webcast that same day at 4:30 p.m. ET.

How can investors join the Journey Medical (DERM) Q2 2026 earnings call on August 12, 2026?

Investors can join the Journey Medical Q2 2026 earnings call by dialing 1-866-777-2509 in the U.S. or 1-412-317-5413 internationally. According to Journey Medical, participants may also register online to receive dial-in details before the 4:30 p.m. ET call.

Will the Journey Medical (DERM) Q2 2026 earnings webcast be available for replay?

Yes. Journey Medical will provide a live audio webcast of the Q2 2026 call on its Investors website. According to Journey Medical, the webcast replay will remain accessible for approximately 30 days following the August 12, 2026 conference call.

Where can I access the Journey Medical (NASDAQ: DERM) Q2 2026 earnings webcast online?

The Q2 2026 earnings webcast for Journey Medical will be available on the News and Events page of the Investors section of its website. According to Journey Medical, the webcast link will stream the live call and support replay for about 30 days.

What type of company is Journey Medical (DERM) and what products does it market?

Journey Medical is a commercial-stage pharmaceutical company focused on dermatology prescription products. According to Journey Medical, it currently markets nine branded FDA-approved prescription drugs that treat common skin conditions through an efficient sales and marketing model in the United States.

What is the relationship between Journey Medical (DERM) and Fortress Biotech (FBIO)?

Journey Medical was founded by Fortress Biotech (Nasdaq: FBIO). According to Journey Medical, it operates as a commercial-stage dermatology-focused pharmaceutical company, with its common stock registered under the Exchange Act and filing periodic reports with the U.S. Securities and Exchange Commission.